The use of cancer vaccines in combination with other cancer therapies is propelling the growth of the cancer vaccines market across the world. In addition factors such as the increasing number of people with cancer, rising public awareness of vaccines and the presence of promising late-stage pipeline candidate programs also enhance growth in the cancer vaccines market.

The field of cancer vaccines is rapidly changing.

Currently, different vaccination strategies such as conjugate-, DNA- and dendritic cell vaccines against tumor cells are being developed with increasing efficacy, SMi’s 5th annual Cancer Vaccines conference provides the perfect platform to delve further in to these strategies and engage in lively discussion within a concentrated and nice peer group.

A combination of cancer vaccines with pharmacotherapeutics remain the preferred choice to treat cancer. This not only increases the efficacy of the treatment but also helps improve the overall survival rate of patients.

SMi’s 5th annual Cancer Vaccines conference will heavily focus on the latest advances in combination therapies and personalised medicines.

The event will bring together leading industry professionals to discuss the immune checkpoint inhibitors and their use in vaccination, development and commercialisation of clinical trials and many more!